SiRNA as a therapy for asthma

Current Opinion in Molecular Therapeutics

Volumn 11, Issue 6, 2009, Pages 652-663

  Huang, Hsin Ying ^a   Chiang, Bor Luen ^a,b  

^a NATIONAL TAIWAN UNIVERSITY   (Taiwan)

^b NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

Author keywords

Allergy; Asthma; Off target effect; RNAi; SiRNA; Therapy

Indexed keywords

CD28 ANTIGEN; CD40 ANTIGEN; CD86 ANTIGEN; EOTAXIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 13; INTERLEUKIN 4; MONOCYTE CHEMOTACTIC PROTEIN 1; SMALL INTERFERING RNA; STAT6 PROTEIN; TRANSCRIPTION FACTOR GATA 3;

ALLERGIC REACTION; ANIMAL MODEL; ASTHMA; CAENORHABDITIS ELEGANS; CELL ACTIVATION; CYTOKINE PRODUCTION; FEASIBILITY STUDY; GENE TARGETING; GENE THERAPY; GENETIC TRANSCRIPTION; HYPERSENSITIVITY; IN VIVO STUDY; INNATE IMMUNITY; MOUSE; NONHUMAN; PROTEIN STABILITY; REVIEW; TH2 CELL; UPREGULATION;

ANIMALS; ANTIGENS, CD40; ANTIGENS, CD86; ASTHMA; CHEMOKINE CCL11; CHEMOKINE CCL2; GATA3 TRANSCRIPTION FACTOR; GENE THERAPY; HUMANS; INTERLEUKIN-13; INTERLEUKIN-4; INTERLEUKIN-5; NF-KAPPA B; RNA INTERFERENCE; RNA STABILITY; RNA, SMALL INTERFERING; STAT6 TRANSCRIPTION FACTOR;

ANIMALIA;

EID: 72449155154     PISSN: 14648431     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (144)

1. Chronic respiratory diseases - Asthma: WHO, Geneva, Switzerland (2009). www.who.int/respiratory/asthma/en
2. Strachan DP: Hay fever, hygiene, and household size. Br Med J (1989) 299(6710):1259-1260.
3. Daniels SE, Bhattacharrya S, James A, Leaves NI, Young A, Hill MR, Faux JA, Ryan GF, le Söuef PN, Lathrop GM, Musk AW et al: A genome-wide search for quantitative trait loci underlying asthma. Nature (1996) 383(6597):247-250.
4. Vercelli D: Discovering susceptibility genes for asthma and allergy. Nat Rev Immunol (2008) 8(3):169-182.
5. Filley WV, Holley KE, Kephart GM, Gleich GJ: Identification by immunofluorescence of eosinophil granule major basic protein in lung tissues of patients with bronchial asthma. Lancet (1982) 2(8288):11-16.
6. Jutel M, Akdis M, Budak F, Aebischer-Casaulta C, Wrzyszcz M, Blaser K, Akdis CA: IL-10 and TGFβ cooperate in the regulatory T cell response to mucosal allergens in normal immunity and specific immunotherapy. Eur J Immunol (2003) 33(5):1205-1214.
7. Akdis M, Akdis CA: Mechanisms of allergen-specific immunotherapy. J Allergy Clin Immunol (2007) 119(4):780-791.
8. Francis JN, Till SJ, Durham SR: Induction of IL-10+CD4+CD25+ T cells by grass pollen immunotherapy. J Allergy Clin Immunol (2003) 111(6):1255-1261.
9. Akdis M, Blaser K, Akdis CA: T regulatory cells in allergy: Novel concepts in the pathogenesis, prevention, and treatment of allergic diseases. J Allergy Clin Immunol (2005) 116(5):961-968.
10. Holgate ST, Djukanovic R, Casale T, Bousquet J: Anti-immunoglobulin E treatment with omalizumab in allergic diseases: An update on anti-inflammatory activity and clinical efficacy. Clin Exp Allergy (2005) 35(4):408-416.
11. Strunk RC, Bloomberg GR: Omalizumab for asthma. N Engl J Med (2006) 354(25):2689-2695.
12. Blanchard C, Mishra A, Saito-Akei H, Monk P, Anderson I, Rothenberg ME: Inhibition of human interleukin-13-induced respiratory and oesophageal inflammation by anti-humaninterleukin- 13 antibody (CAT-354). Clin Exp Allergy (2005) 35(8):1096-1103.
13. O'Byrne P, Boulet L, Gauvreau G, Leon F, Sari S, White B: A single dose of MEDI-528, a monoclonal antibody against interleukin-9, is well tolerated in mild and moderate asthmatics in the phase II trail MI-CP-138. Chest (2007) 132(4):478S.
14. Sur S, Wild JS, Choudhury BK, Sur N, Alam R, Klinman DM: Long term prevention of allergic lung inflammation in a mouse model of asthma by CpG oligodeoxynucleotides. J Immunol (1999) 162(10):6284-6293.
15. Kline JN, Kitagaki K, Businga TR, Jain VV: Treatment of established asthma in a murine model using CpG oligodeoxynucleotides. Am J Physiol Lung Cell Mol Physiol (2002) 283(1):L170-L179.
16. Kitagaki K, Businga TR, Kline JN: Oral administration of CpG-ODNs suppresses antigen-induced asthma in mice. Clin Exp Immunol (2006) 143(2):249-259.
17. Jain VV, Kitagaki K, Businga T, Hussain I, George C, O'Shaughnessy P, Kline JN: CpG-oligodeoxynucleotides inhibit airway remodeling in a murine model of chronic asthma. J Allergy Clin Immunol (2002) 110(6):867-872.
18. Hirose I, Tanaka H, Takahashi G, Wakahara K, Tamari M, Sakamoto T, Kojima S, Inagaki N, Nagai H: Immunomodulatory effects of CpG oligodeoxynucleotides on house dust miteinduced airway inflammation in mice. Int Arch Allergy Immunol (2008) 147(1):6-16.
19. Roy K, Mao HQ, Huang SK, Leong KW: Oral gene delivery with chitosan-DNA nanoparticles generates immunologic protection in a murine model of peanut allergy. Nat Med (1999) 5(4):387-391.
20. Kim CH, Ahn JH, Kim SJ, Lee SY, Kim YK, Kim KH, Moon HS, Song JS, Park SH, Kwon SS: Co-administration of vaccination with DNA encoding T cell epitope on the Der p and BCG inhibited airway remodeling in a murine model of chronic asthma. J Asthma (2006) 43(5):345-353.
21. Popescu FD: Antisense- and RNA interference-based therapeutic strategies in allergy. J Cell Mol Med (2005) 9(4): 840-853.
22. Wang LC, Lee JH, Yang YH, Lin YT, Chiang BL: New biological approaches in asthma: DNA-based therapy. Curr Med Chem (2007) 14(15):1607-1618.
23. Popescu FD, Popescu F: A review of antisense therapeutic interventions for molecular biological targets in asthma. Biologics (2007) 1(3):271-283.
24. Fire A, Xu S, Montgomery MK, Kostas SA, Driver SE, Mello CC: Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans. Nature (1998) 391(6669): 806-811. (Pubitemid 28099681)
25. Elbashir SM, Harborth J, Lendeckel W, Yalcin A, Weber K, Tuschl T: Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells. Nature (2001) 411(6836):494-498.
26. Ngô H, Tschudi C, Gull K, Ullu E: Double-stranded RNA induces mRNA degradation in Trypanosoma brucei. Proc Natl Acad Sci USA (1998) 95(25):14687-14692.
27. Montgomery MK, Xu S, Fire A: RNA as a target of double-stranded RNA-mediated genetic interference in Caenorhabditis elegans. Proc Natl Acad Sci USA (1998) 95(26):15502-15507. (Pubitemid 29018728)
28. Tuschl T, Zamore PD, Lehmann R, Bartel DP, Sharp PA: Targeted mRNA degradation by double-stranded RNA in vitro. Genes Dev (1999) 13(24):3191-3197.
29. Zamore PD, Tuschl T, Sharp PA, Bartel DP: RNAi: Double-stranded RNA directs the ATP-dependent cleavage of mRNA at 21 to 23 nucleotide intervals. Cell (2000) 101(1):25-33.
30. Hamilton AJ, Baulcombe DC: A species of small antisense RNA in posttranscriptional gene silencing in plants. Science (1999) 286(5441):950-952.
31. Hammond SM, Bernstein E, Beach D, Hannon GJ: An RNA-directed nuclease mediates post-transcriptional gene silencing in Drosophila cells. Nature (2000) 404(6775):293-296.
32. Bernstein E, Caudy AA, Hammond SM, Hannon GJ: Role for a bidentate ribonuclease in the initiation step of RNA interference. Nature (2001) 409(6818):363-366.
33. Hammond SM, Boettcher S, Caudy AA, Kobayashi R, Hannon GJ: Argonaute2, a link between genetic and biochemical analyses of RNAi. Science (2001) 293(5532):1146-1150.
34. Caudy AA, Ketting RF, Hammond SM, Denli AM, Bathoorn AM, Tops BB, Silva JM, Myers MM, Hannon GJ, Plasterk RH: A micrococcal nuclease homologue in RNAi effector complexes. Nature (2003) 425(6956):411-414.
35. Liu J, Carmell MA, Rivas FV, Marsden CG, Thomson JM, Song JJ, Hammond SM, Joshua-Tor L, Hannon GJ: Argonaute2 is the catalytic engine of mammalian RNAi. Science (2004) 305(5689):1437-1441.
36. Song JJ, Smith SK, Hannon GJ, Joshua-Tor L: Crystal structure of Argonaute and its implications for RISC slicer activity. Science (2004) 305(5689):1434-1437.
37. Morris KV, Chan SW, Jacobsen SE, Looney DJ: Small interfering RNA-induced transcriptional gene silencing in human cells. Science (2004) 305(5688):1289-1292.
38. Kawasaki H, Taira K: Induction of DNA methylation and gene silencing by short interfering RNAs in human cells. Nature (2004) 431(7005):211-217.
39. Kawasaki H, Taira K, Morris KV: siRNA induced transcriptional gene silencing in mammalian cells. Cell Cycle (2005) 4(3): 442-448.
40. Hawkins PG, Morris KV: RNA and transcriptional modulation of gene expression. Cell Cycle (2008) 7(5):602-607.
41. Djupedal I, Ekwall K: Epigenetics: Heterochromatin meets RNAi. Cell Res (2009) 19(3):282-295.
42. Zamecnik PC, Stephenson ML: Inhibition of Rous sarcoma virus replication and cell transformation by a specific oligodeoxynucleotide. Proc Natl Acad Sci USA (1978) 75(1):280-284.
43. Dash P, Lotan I, Knapp M, Kandel ER, Goelet P: Selective elimination of mRNAs in vivo: Complementary oligodeoxynucleotides promote RNA degradation by an RNase H-like activity. Proc Natl Acad Sci USA (1987) 84(22): 7896-7900.
44. Mercatante DR, Kole R: Control of alternative splicing by antisense oligonucleotides as a potential chemotherapy: Effects on gene expression. Biochim Biophys Acta (2002) 1587 (2-3):126-132.
45. Bertrand JR, Pottier M, Vekris A, Opolon P, Maksimenko A, Malvy C: Comparison of antisense oligonucleotides and siRNAs in cell culture and in vivo. Biochem Biophys Res Commun (2002) 296(4):1000-1004.
46. Winkler J, Noe CR: Oligonucleotide charge reversal: 2'-O-lysylaminohexyl modified oligonucleotides. Nucleosides Nucleotides Nucleic Acids (2007) 26(8-9):939-942.
47. Nagahama K, Veedu RN, Wengel J: Nuclease resistant methylphosphonate-DNA/ LNA chimeric oligonucleotides. Bioorg Med Chem Lett (2009) 19(10):2707-2709.
48. Gleave ME, Monia BP: Antisense therapy for cancer. Nat Rev Cancer (2005) 5(6):468-479.
49. Heinonen JE, Smith CI, Nore BF: Silencing of Bruton's tyrosine kinase (Btk) using short interfering RNA duplexes (siRNA). FEBS Lett (2002) 527(1-3):274-278.
50. Nigo YI, Yamashita M, Hirahara K, Shinnakasu R, Inami M, Kimura M, Hasegawa A, Kohno Y, Nakayama T: Regulation of allergic airway inflammation through Toll-like receptor 4-mediated modification of mast cell function. Proc Natl Acad Sci USA (2006) 103(7):2286-2291.
51. Maneechotesuwan K, Xin Y, Ito K, Jazrawi E, Lee KY, Usmani OS, Barnes PJ, Adcock IM: Regulation of Th2 cytokine genes by p38 MAPK-mediated phosphorylation of GATA-3. J Immunol (2007) 178(4):2491-2498.
52. Trian T, Girodet PO, Ousova O, Marthan R, Tunon-de-Lara JM, Berger P: RNA interference decreases PAR-2 expression and function in human airway smooth muscle cells. Am J Respir Cell Mol Biol (2006) 34(1):49-55.
53. Oettgen HC: Regulation of the IgE isotype switch: New insights on cytokine signals and the functions of ε germline transcripts. Curr Opin Immunol (2000) 12(6):618-623.
54. Linhart B, Bigenzahn S, Hartl A, Lupinek C, Thalhamer J, Valenta R, Wekerle T: Costimulation blockade inhibits allergic sensitization but does not affect established allergy in a murine model of grass pollen allergy. J Immunol (2007) 178(6):3924-3931.
55. Knechtle SJ: Knowledge about transplantation tolerance gained in primates. Curr Opin Immunol (2000) 12(5):552-556.
56. Suzuki M, Zheng X, Zhang X, Li M, Vladau C, Ichim TE, Sun H, Min LR, Garcia B, Min WP: Novel vaccination for allergy through gene silencing of CD40 using small interfering RNA. J Immunol (2008) 180(12):8461-8469.
57. Larche M, Till SJ, Haselden BM, North J, Barkans J, Corrigan CJ, Kay AB, Robinson DS: Costimulation through CD86 is involved in airway antigen-presenting cell and T cell responses to allergen in atopic asthmatics. J Immunol (1998) 161(11): 6375-6382.
58. Crosby JR, Guha M, Tung D, Miller DA, Bender B, Condon TP, York-DeFalco C, Geary RS, Monia BP, Karras JG, Gregory SA: Inhaled CD86 antisense oligonucleotide suppresses pulmonary inflammation and airway hyper-responsiveness in allergic mice. J Pharmacol Exp Ther (2007) 321(3):938-946.
59. Ritprajak P, Hashiguchi M, Azuma M: Topical application of cream-emulsified CD86 siRNA ameliorates allergic skin disease by targeting cutaneous dendritic cells. Mol Ther (2008) 16(7):1323-1330.
60. Pai SY, Truitt ML, Ho IC: GATA-3 deficiency abrogates the development and maintenance of T helper type 2 cells. Proc Natl Acad Sci USA (2004) 101(7):1993-1998.
61. Zhu J, Min B, Hu-Li J, Watson CJ, Grinberg A, Wang Q, Killeen N, Urban JF Jr, Guo L, Paul WE: Conditional deletion of Gata3 shows its essential function in Th1-Th2 responses. Nat Immunol (2004) 5(11):1157-1165.
62. Nakamura Y, Ghaffar O, Olivenstein R, Taha RA, Soussi-Gounni A, Zhang DH, Ray A, Hamid Q: Gene expression of the GATA-3 transcription factor is increased in atopic asthma. J Allergy Clin Immunol (1999) 103(2 Pt 1):215-222.
63. Zhang DH, Yang L, Cohn L, Parkyn L, Homer R, Ray P, Ray A: Inhibition of allergic inflammation in a murine model of asthma by expression of a dominant-negative mutant of GATA-3. Immunity (1999) 11(4):473-482.
64. Finotto S, De Sanctis GT, Lehr HA, Herz U, Buerke M, Schipp M, Bartsch B, Atreya R, Schmitt E, Galle PR, Renz H et al: Treatment of allergic airway inflammation and hyperresponsiveness by antisense-induced local blockade of GATA-3 expression. J Exp Med (2001) 193(11):1247-1260.
65. Lee CC, Huang HY, Chiang BL: Lentiviral-mediated GATA-3 RNAi decreases allergic airway inflammation and hyperresponsiveness. Mol Ther (2008) 16(1):60-65.
66. Sel S, Wegmann M, Dicke T, Sel S, Henke W, Yildirim AO, Renz H, Garn H: Effective prevention and therapy of experimental allergic asthma using a GATA-3-specific DNAzyme. J Allergy Clin Immunol (2008) 121(4)910-916.e5.
67. Takeda K, Tanaka T, Shi W, Matsumoto M, Minami M, Kashiwamura S, Nakanishi K, Yoshida N, Kishimoto T, Akira S: Essential role of STAT6 in IL-4 signalling. Nature (1996) 380(6575):627-630.
68. Akiho H, Blennerhassett P, Deng Y, Collins SM: Role of IL-4, IL-13, and STAT6 in inflammation-induced hypercontractility of murine smooth muscle cells. Am J Physiol Gastrointest Liver Physiol (2002) 282(2):G226-G232.
69. Christodoulopoulos P, Cameron L, Nakamura Y, Lemiere C, Muro S, Dugas M, Boulet LP, Laviolette M, Olivenstein R, Hamid Q: Th2 cytokine-associated transcription factors in atopic and nonatopic asthma: Evidence for differential signal transducer and activator of transcription 6 expression. J Allergy Clin Immunol (2001) 107(4):586-591.
70. Shimoda K, van Deursen J, Sangster MY, Sarawar SR, Carson RT, Tripp RA, Chu C, Quelle FW, Nosaka T, Vignali DA, Doherty PC et al: Lack of IL-4-induced Th2 response and IgE class switching in mice with disrupted STAT6 gene. Nature (1996) 380(6575): 630-633.
71. Tomkinson A, Kanehiro A, Rabinovitch N, Joetham A, Cieslewicz G, Gelfand EW: The failure of STAT6-deficient mice to develop airway eosinophilia and airway hyperresponsiveness is overcome by interleukin-5. Am J Respir Crit Care Med (1999) 160(4):1283-1291.
72. Walker W, Healey GD, Hopkin JM: RNA interference of STAT6 rapidly attenuates ongoing interleukin-13-mediated events in lung epithelial cells. Immunology (2009) 127(2):256-266.
73. Darcan-Nicolaisen Y, Meinicke H, Fels G, Hegend O, Haberland A, Kuhl A, Loddenkemper C, Witzenrath M, Kube S, Henke W, Hamelmann E: Small interfering RNA against transcription factor STAT6 inhibits allergic airway inflammation and hyperreactivity in mice. J Immunol (2009) 182(12):7501-7508.
74. Gagliardo R, Chanez P, Mathieu M, Bruno A, Costanzo G, Gougat C, Vachier I, Bousquet J, Bonsignore G, Vignola AM: Persistent activation of nuclear factor-κB signaling pathway in severe uncontrolled asthma. Am J Respir Crit Care Med (2003) 168(10):1190-1198.
75. La Grutta S, Gagliardo R, Mirabella F, Pajno GB, Bonsignore G, Bousquet J, Bellia V, Vignola AM: Clinical and biological heterogeneity in children with moderate asthma. Am J Respir Crit Care Med (2003) 167(11):1490-1495.
76. Hart LA, Krishnan VL, Adcock IM, Barnes PJ, Chung KF: Activation and localization of transcription factor, nuclear factor-κB, in asthma. Am J Respir Crit Care Med (1998) 158(5 Pt 1):1585-1592.
77. Zhao S, Qi Y, Liu X, Jiang Q, Liu S, Jiang Y, Jiang Z: Activation of NF-κB in bronchial epithelial cells from children with asthma. Chin Med J (Engl) (2001) 114(9):909-911.
78. Yang L, Cohn L, Zhang DH, Homer R, Ray A, Ray P: Essential role of nuclear factor κB in the induction of eosinophilia in allergic airway inflammation. J Exp Med (1998) 188(9):1739-1750.
79. Choi IW, Kim DK, Ko HM, Lee HK: Administration of antisense phosphorothioate oligonucleotide to the p65 subunit of NF-κB inhibits established asthmatic reaction in mice. Int Immunopharmacol (2004) 4(14):1817-1828.
80. Hamelmann E, Takeda K, Haczku A, Cieslewicz G, Shultz L, Hamid Q, Xing Z, Gauldie J, Gelfand EW: Interleukin (IL)-5 but not immunoglobulin E reconstitutes airway inflammation and airway hyperresponsiveness in IL-4-deficient mice. Am J Respir Cell Mol Biol (2000) 23(3):327-334.
81. Molet S, Ramos-Barbón D, Martin JG, Hamid Q: Adoptively transferred late allergic response is inhibited by IL-4, but not IL-5, antisense oligonucleotide. J Allergy Clin Immunol (1999) 104(1):205-214.
82. Lively TN, Kossen K, Balhorn A, Koya T, Zinnen S, Takeda K, Lucas JJ, Polisky B, Richards IM, Gelfand EW: Effect of chemically modified IL-13 short interfering RNA on development of airway hyperresponsiveness in mice. J Allergy Clin Immunol (2008) 121(1):88-94.
83. Yamaguchi Y, Suda T, Suda J, Eguchi M, Miura Y, Harada N, Tominaga A, Takatsu K: Purified interleukin 5 supports the terminal differentiation and proliferation of murine eosinophilic precursors. J Exp Med (1988) 167(1):43-56.
84. Sanderson CJ: Interleukin-5: An eosinophil growth and activation factor. Dev Biol Stand (1988) 69:23-29.
85. Collins PD, Marleau S, Griffiths-Johnson DA, Jose PJ, Williams TJ: Cooperation between interleukin-5 and the chemokine eotaxin to induce eosinophil accumulation in vivo. J Exp Med (1995) 182(4):1169-1174.
86. Fujisawa T, Kato Y, Nagase H, Atsuta J, Terada A, Iguchi K, Kamiya H, Morita Y, Kitaura M, Kawasaki H, Yoshie O et al: Chemokines induce eosinophil degranulation through CCR-3. J Allergy Clin Immunol (2000) 106(3):507-513.
87. Humbert M, Corrigan CJ, Kimmitt P, Till SJ, Kay AB, Durham SR: Relationship between IL-4 and IL-5 mRNA expression and disease severity in atopic asthma. Am J Respir Crit Care Med (1997) 156(3 Pt 1):704-708.
88. Robinson D, Hamid Q, Bentley A, Ying S, Kay AB, Durham SR: Activation of CD4+ T cells, increased Th2-type cytokine mRNA expression, and eosinophil recruitment in bronchoalveolar lavage after allergen inhalation challenge in patients with atopic asthma. J Allergy Clin Immunol (1993) 92(2):313-324.
89. Karras JG, McGraw K, McKay RA, Cooper SR, Lerner D, Lu T, Walker C, Dean NM, Monia BP: Inhibition of antigen-induced eosinophilia and late phase airway hyperresponsiveness by an IL-5 antisense oligonucleotide in mouse models of asthma. J Immunol (2000) 164(10):5409-5415.
90. Huang HY, Lee CC, Chiang BL: Small interfering RNA against interleukin-5 decreases airway eosinophilia and hyperresponsiveness. Gene Ther (2008) 15(9):660-667.
91. Pease JE, Williams TJ: Eotaxin and asthma. Curr Opin Pharmacol (2001) 1(3):248-253.
92. Fortin M, Ferrari N, Higgins ME, Séguin S, Allam M, Allakhverdi Z, Piaget-Rodriguez C, Paquet L, Renzi PM: Effects of antisense oligodeoxynucleotides targeting CCR3 on the airway response to antigen in rats. Oligonucleotides (2006) 16(3):203-212.
93. Huang HY, Lee CC, Chiang BL: Short hairpin RNAs against eotaxin or interleukin-5 decrease airway eosinophilia and hyper-responsiveness in a murine model of asthma. J Gene Med (2009) 11(2):112-118.
94. Carr MW, Roth SJ, Luther E, Rose SS, Springer TA: Monocyte chemoattractant protein 1 acts as a T-lymphocyte chemoattractant. Proc Natl Acad Sci USA (1994) 91(9):3652-3656.
95. Loetscher P, Seitz M, Clark-Lewis I, Baggiolini M, Moser B: Monocyte chemotactic proteins MCP-1, MCP-2, and MCP-3 are major attractants for human CD4+ and CD8+ Tlymphocytes. FASEB J (1994) 8(13):1055-1060.
96. Allavena P, Bianchi G, Zhou D, van Damme J, Jilek P, Sozzani S, Mantovani A: Induction of natural killer cell migration by monocyte chemotactic protein-1, -2 and -3. Eur J Immunol (1994) 24(12):3233-3236.
97. Alam R, Lett-Brown MA, Forsythe PA, Anderson-Walters DJ, Kenamore C, Kormos C, Grant JA: Monocyte chemotactic and activating factor is a potent histamine-releasing factor for basophils. J Clin Invest (1992) 89(3):723-728.
98. Alam R, Kumar D, Anderson-Walters D, Forsythe PA: Macrophage inflammatory protein-1 α and monocyte chemoattractant peptide-1 elicit immediate and late cutaneous reactions and activate murine mast cells in vivo. J Immunol (1994) 152(3):1298-1303.
99. Gu L, Tseng S, Horner RM, Tam C, Loda M, Rollins BJ: Control of Th2 polarization by the chemokine monocyte chemoattractant protein-1. Nature (2000) 404(6776):407-411.
100. Gharaee-Kermani M, Denholm EM, Phan SH: Costimulation of fibroblast collagen and transforming growth factor β1 gene expression by monocyte chemoattractant protein-1 via specific receptors. J Biol Chem (1996) 271(30):17779-17784.
101. Ishimoto T, Takei Y, Yuzawa Y, Hanai K, Nagahara S, Tarumi Y, Matsuo S, Kadomatsu K: Downregulation of monocyte chemoattractant protein-1 involving short interfering RNA attenuates hapten-induced contact hypersensitivity. Mol Ther (2008) 16(2):387-395.
102. Lu PY, Woodle MC: Delivering small interfering RNA for novel therapeutics. Methods Mol Biol (2008) 437:93-107.
103. Dykxhoorn DM, Lieberman J: Running interference: Prospects and obstacles to using small interfering RNAs as small molecule drugs. Annu Rev Biomed Eng (2006) 8:377-402.
104. Oliveira S, Storm G, Schiffelers RM: Targeted delivery of siRNA. J Biomed Biotechnol (2006) 2006(4):63675.
105. Soutschek J, Akinc A, Bramlage B, Charisse K, Constien R, Donoghue M, Elbashir S, Geick A, Hadwiger P, Harborth J, John M et al: Therapeutic silencing of an endogenous gene by systemic administration of modified siRNAs. Nature (2004) 432(7014): 173-178.
106. Griesenbach U, Kitson C, Escudero Garcia S, Farley R, Singh C, Somerton L, Painter H, Smith RL, Gill DR, Hyde SC, Chow YH et al: Inefficient cationic lipid-mediated siRNA and antisense oligonucleotide transfer to airway epithelial cells in vivo. Respir Res (2006) 7:26.
107. DeVincenzo J, Cehelsky JE, Alvarez R, Elbashir S, Harborth J, Toudjarska I, Nechev L, Murugaiah V, Van Vliet A, Vaishnaw AK, Meyers R: Evaluation of the safety, tolerability and pharmacokinetics of ALN-RSV01, a novel RNAi antiviral therapeutic directed against respiratory syncytial virus (RSV). Antiviral Res (2008) 77(3):225-231.
108. Winkler J, Gilbert M, Kocourková A, Stessl M, Noe CR: 2'-O-lysylaminohexyl oligonucleotides: Modifications for antisense and siRNA. ChemMedChem (2008) 3(1):102-110.
109. Barquinero J, Eixarch H, Perez-Melgosa M: Retroviral vectors: New applications for an old tool. Gene Ther (2004) 11 (Suppl 1):S3-S9.
110. Grimm D, Streetz KL, Jopling CL, Storm TA, Pandey K, Davis CR, Marion P, Salazar F, Kay MA: Fatality in mice due to oversaturation of cellular microRNA/short hairpin RNA pathways. Nature (2006) 441(7092):537-541.
111. Grimm D, Kay MA: RNAi and gene therapy: A mutual attraction. Hematol Am Soc Hematol Educ Program (2007):473-481.
112. Gao K, Huang L: Nonviral methods for siRNA delivery. Mol Pharm (2009) 6(3):651-658.
113. Paddison PJ, Hannon GJ: RNA interference: The new somatic cell genetics? Cancer Cell (2002) 2(1):17-23. (Pubitemid 41051018)
114. Takahashi Y, Yamaoka K, Nishikawa M, Takakura Y: Quantitative and temporal analysis of gene silencing in tumor cells induced by small interfering RNA or short hairpin RNA expressed from plasmid vectors. J Pharm Sci (2009) 98(1):74-80.
115. Wiznerowicz M, Szulc J, Trono D: Tuning silence: Conditional systems for RNA interference. Nat Methods (2006) 3(9):682-688.
116. Yuan J, Wang X, Zhang Y, Hu X, Deng X, Fei J, Li N: shRNA transcribed by RNA Pol II promoter induce RNA interference in mammalian cell. Mol Biol Rep (2006) 33(1):43-49.
117. Rao MK, Wilkinson MF: Tissue-specific and cell type-specific RNA interference in vivo. Nat Protoc (2006) 1(3):1494-1501.
118. Rao MK, Pham J, Imam JS, MacLean JA, Murali D, Furuta Y, Sinha-Hikim AP, Wilkinson MF: Tissue-specific RNAi reveals that WT1 expression in nurse cells controls germ cell survival and spermatogenesis. Genes Dev (2006) 20(2):147-152.
119. Charalambopoulou GC, Kikkinides ES, Papadokostaki KG, Stubos AK, Papaioannou AT: Numerical and experimental investigation of the diffusional release of a dispersed solute from polymeric multilaminate matrices. J Control Release (2001) 70(3):309-319.
120. Schiffelers RM, Ansari A, Xu J, Zhou Q, Tang Q, Storm G, Molema G, Lu PY, Scaria PV, Woodle MC: Cancer siRNA therapy by tumor selective delivery with ligand-targeted sterically stabilized nanoparticle. Nucleic Acids Res (2004) 32(19):e149.
121. Liu B: Exploring cell type-specific internalizing antibodies for targeted delivery of siRNA. Brief Funct Genomic Proteomic (2007) 6(2):112-119.
122. Marques JT, Williams BR: Activation of the mammalian immune system by siRNAs. Nat Biotechnol (2005) 23(11):1399-1405.
123. Jackson AL, Bartz SR, Schelter J, Kobayashi SV, Burchard J, Mao M, Li B, Cavet G, Linsley PS: Expression profiling reveals off-target gene regulation by RNAi. Nat Biotechnol (2003) 21(6):635-637.
124. Jackson AL, Burchard J, Schelter J, Chau BN, Cleary M, Lim L, Linsley PS: Widespread siRNA "off-target" transcript silencing mediated by seed region sequence complementarity. RNA (2006) 12(7):1179-1187.
125. Jackson AL, Burchard J, Leake D, Reynolds A, Schelter J, Guo J, Johnson JM, Lim L, Karpilow J, Nichols K, Marshall W et al: Position-specific chemical modification of siRNAs reduces "offtarget" transcript silencing. RNA (2006) 12(7):1197-1205.
126. Birmingham A, Anderson EM, Reynolds A, Ilsley-Tyree D, Leake D, Fedorov Y, Baskerville S, Maksimova E, Robinson K, Karpilow J, Marshall WS et al: 3' UTR seed matches, but not overall identity, are associated with RNAi off-targets. Nat Methods (2006) 3(3):199-204.
127. Bartel DP: MicroRNAs: Genomics, biogenesis, mechanism, and function. Cell (2004) 116(2):281-297.
128. Samuel CE: The eIF-2 α protein kinases, regulators of translation in eukaryotes from yeasts to humans. J Biol Chem (1993) 268(11):7603-7606.
129. Hovanessian AG: On the discovery of interferon-inducible, double-stranded RNA activated enzymes: The 2'-5' oligoadenylate synthetases and the protein kinase PKR. Cytokine Growth Factor Rev (2007) 18(5-6):351-361.
130. Lemaire PA, Anderson E, Lary J, Cole JL: Mechanism of PKR activation by dsRNA. J Mol Biol (2008) 381(2):351-360.
131. Sledz CA, Holko M, de Veer MJ, Silverman RH, Williams BR: Activation of the interferon system by short-interfering RNAs. Nat Cell Biol (2003) 5(9):834-839.
132. Bridge AJ, Pebernard S, Ducraux A, Nicoulaz AL, Iggo R: Induction of an interferon response by RNAi vectors in mammalian cells. Nat Genet (2003) 34(3):263-264.
133. Heil F, Hemmi H, Hochrein H, Ampenberger F, Kirschning C, Akira S, Lipford G, Wagner H, Bauer S: Species-specific recognition of single-stranded RNA via toll-like receptor 7 and 8. Science (2004) 303(5663):1526-1529.
134. Hornung V, Guenthner-Biller M, Bourquin C, Ablasser A, Schlee M, Uematsu S, Noronha A, Manoharan M, Akira S, de Fougerolles A, Endres S et al: Sequence-specific potent induction of IFN-α by short interfering RNA in plasmacytoid dendritic cells through TLR7. Nat Med (2005) 11(3):263-270.
135. Judge AD, Sood V, Shaw JR, Fang D, McClintock K, MacLachlan I: Sequence-dependent stimulation of the mammalian innate immune response by synthetic siRNA. Nat Biotechnol (2005) 23(4):457-462.
136. Sioud M: Single-stranded small interfering RNA are more immunostimulatory than their double-stranded counterparts: A central role for 2'-hydroxyl uridines in immune responses. Eur J Immunol (2006) 36(5):1222-1230.
137. Pauls E, Senserrich J, Bofill M, Clotet B, Este JA: Induction of interleukins IL-6 and IL-8 by siRNA. Clin Exp Immunol (2007) 147(1):189-196.
138. Hutvagner G, Simard MJ, Mello CC, Zamore PD: Sequence-specific inhibition of small RNA function. PLoS Biol (2004) 2(4):E98.
139. Kim DH, Longo M, Han Y, Lundberg P, Cantin E, Rossi JJ: Interferon induction by siRNAs and ssRNAs synthesized by phage polymerase. Nat Biotechnol (2004) 22(3):321-325.
140. Robbins M, Judge A, Liang L, McClintock K, Yaworski E, MacLachlan I: 2'-O-methyl-modified RNAs act as TLR7 antagonists. Mol Ther (2007) 15(9):1663-1669.
141. Sioud M: Induction of inflammatory cytokines and interferon responses by double-stranded and single-stranded siRNAs is sequence-dependent and requires endosomal localization. J Mol Biol (2005) 348(5):1079-1090.
142. Shin D, Kim SI, Park M, Kim M: Immunostimulatory properties and antiviral activity of modified HBV-specific siRNAs. Biochem Biophys Res Commun (2007) 364(3):436-442.
143. Lai WQ, Goh HH, Bao Z, Wong WS, Melendez AJ, Leung BP: The role of sphingosine kinase in a murine model of allergic asthma. J Immunol (2008) 180(6):4323-4329.
144. Wang X, Xu W, Mohapatra S, Kong X, Li X, Lockey RF, Mohapatra SS: Prevention of airway inflammation with topical cream containing imiquimod and small interfering RNA for natriuretic peptide receptor. Genet Vaccines Ther (2008) 6:7.